Skip to main content
Log in

Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever

  • Case Report
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by self-limited recurrent attacks of fever and serositis. The serious complication of FMF is AA-type amyloidosis, which can result in end-stage renal disease. Although colchicine is effective in the majority of patients, there is no established treatment for those who are resistant or intolerant to colchicine. We herein report the efficacy of anakinra in a 52-year-old Turkish patient with FMF, secondary amyloidosis and renal transplant, who was resistant to colchicine treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Touitou I (2001) The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet 9:473–483

    Article  PubMed  CAS  Google Scholar 

  2. Lidar M, Scherrmann JM, Shinar Y et al (2004) Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetical, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 33:273–282

    Article  PubMed  CAS  Google Scholar 

  3. Tunca M, Akar S, Soytürk M et al (2004) The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Clin Exp Rheumatol 22:37–40

    Google Scholar 

  4. Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A (2007) Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol 13:38–40

    Article  PubMed  Google Scholar 

  5. Chae JJ, Wood G, Masters SL et al (2006) The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc Natl Acad Sci 103:9982–9987

    Article  PubMed  CAS  Google Scholar 

  6. Cohen S, Hurd E, Cush J et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614–624

    Article  PubMed  CAS  Google Scholar 

  7. Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M (1992) Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 60:418–422

    Article  PubMed  CAS  Google Scholar 

  8. Calligaris L, Marchetti F, Tommasini A, Ventura A (2008) The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 167:695–696

    Article  PubMed  Google Scholar 

  9. Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ (2007) Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66(11):1545–1546

    Article  PubMed  Google Scholar 

  10. Moser C, Pohl G, Haslinger I et al (2009) Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant 24:676–678

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nilüfer Alpay.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alpay, N., Şumnu, A., Çalışkan, Y. et al. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int 32, 3277–3279 (2012). https://doi.org/10.1007/s00296-010-1474-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-010-1474-6

Keywords

Navigation